Pharming Group (PHAR) Competitors $13.70 +1.04 (+8.21%) Closing price 08/22/2025 03:52 PM EasternExtended Trading$13.27 -0.43 (-3.14%) As of 08/22/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAR vs. BHC, KYMR, SRRK, AMRX, XENE, CRNX, HCM, RARE, MOR, and ARWRShould you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Bausch Health Cos (BHC), Kymera Therapeutics (KYMR), Scholar Rock (SRRK), Amneal Pharmaceuticals (AMRX), Xenon Pharmaceuticals (XENE), Crinetics Pharmaceuticals (CRNX), HUTCHMED (HCM), Ultragenyx Pharmaceutical (RARE), MorphoSys (MOR), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry. Pharming Group vs. Its Competitors Bausch Health Cos Kymera Therapeutics Scholar Rock Amneal Pharmaceuticals Xenon Pharmaceuticals Crinetics Pharmaceuticals HUTCHMED Ultragenyx Pharmaceutical MorphoSys Arrowhead Pharmaceuticals Pharming Group (NASDAQ:PHAR) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment. Which has more risk & volatility, PHAR or BHC? Pharming Group has a beta of 0.02, meaning that its share price is 98% less volatile than the S&P 500. Comparatively, Bausch Health Cos has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Which has preferable valuation & earnings, PHAR or BHC? Pharming Group has higher earnings, but lower revenue than Bausch Health Cos. Pharming Group is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPharming Group$297.20M3.16-$11.84M-$0.13-105.38Bausch Health Cos$9.63B0.29-$46M$0.2628.77 Do analysts recommend PHAR or BHC? Pharming Group currently has a consensus target price of $30.00, suggesting a potential upside of 118.98%. Bausch Health Cos has a consensus target price of $9.00, suggesting a potential upside of 20.30%. Given Pharming Group's stronger consensus rating and higher probable upside, equities analysts plainly believe Pharming Group is more favorable than Bausch Health Cos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pharming Group 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Bausch Health Cos 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is PHAR or BHC more profitable? Bausch Health Cos has a net margin of 0.99% compared to Pharming Group's net margin of -2.19%. Pharming Group's return on equity of -3.31% beat Bausch Health Cos' return on equity.Company Net Margins Return on Equity Return on Assets Pharming Group-2.19% -3.31% -1.78% Bausch Health Cos 0.99%-852.36%5.25% Does the media prefer PHAR or BHC? In the previous week, Bausch Health Cos had 16 more articles in the media than Pharming Group. MarketBeat recorded 16 mentions for Bausch Health Cos and 0 mentions for Pharming Group. Pharming Group's average media sentiment score of 0.99 beat Bausch Health Cos' score of 0.10 indicating that Pharming Group is being referred to more favorably in the media. Company Overall Sentiment Pharming Group Positive Bausch Health Cos Neutral Do insiders and institutionals believe in PHAR or BHC? 0.0% of Pharming Group shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 8.1% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryBausch Health Cos beats Pharming Group on 9 of the 16 factors compared between the two stocks. Get Pharming Group News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAR vs. The Competition Export to ExcelMetricPharming GroupMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$938.65M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-105.3821.0031.3626.05Price / Sales3.16209.44387.8788.42Price / Cash184.8144.5038.0259.36Price / Book3.918.129.536.60Net Income-$11.84M-$54.72M$3.26B$265.65M7 Day Performance17.60%2.62%2.14%2.00%1 Month Performance36.32%3.25%3.22%0.46%1 Year Performance81.22%10.82%30.18%18.88% Pharming Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHARPharming Group2.3672 of 5 stars$13.70+8.2%$30.00+119.0%+80.3%$938.65M$297.20M-105.38280Gap UpBHCBausch Health Cos4.18 of 5 stars$8.02-3.8%$9.00+12.2%+27.6%$3.09B$9.63B30.8520,700Positive NewsAnalyst RevisionKYMRKymera Therapeutics2.7175 of 5 stars$43.62+2.3%$59.11+35.5%-7.7%$3.05B$47.07M-12.57170SRRKScholar Rock4.5806 of 5 stars$31.52+0.4%$45.14+43.2%+282.8%$3.02B$33.19M-10.83140News CoveragePositive NewsAnalyst ForecastAMRXAmneal Pharmaceuticals3.3271 of 5 stars$9.26-2.0%$11.60+25.3%+14.4%$2.97B$2.85B926.938,100News CoveragePositive NewsInsider TradeXENEXenon Pharmaceuticals2.0478 of 5 stars$37.82-1.1%$53.20+40.7%-4.7%$2.95B$9.43M-10.65210News CoverageOptions VolumeCRNXCrinetics Pharmaceuticals3.6646 of 5 stars$29.74-3.2%$68.86+131.5%-41.8%$2.89B$1.04M-7.24210News CoverageInsider TradeHCMHUTCHMED2.6623 of 5 stars$16.43-0.1%$28.00+70.4%-6.7%$2.87B$602.20M0.001,811RAREUltragenyx Pharmaceutical4.7276 of 5 stars$29.70+0.0%$81.50+174.4%-47.5%$2.86B$610.16M-5.371,294News CoverageMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsARWRArrowhead Pharmaceuticals3.7591 of 5 stars$19.91-2.9%$43.14+116.7%-13.9%$2.84B$3.55M-15.55400 Related Companies and Tools Related Companies BHC Competitors KYMR Competitors SRRK Competitors AMRX Competitors XENE Competitors CRNX Competitors HCM Competitors RARE Competitors MOR Competitors ARWR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAR) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharming Group N.V. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharming Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access